๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma: A pilot study

โœ Scribed by F. Mirici Cappa; M.C. Cantarini; G. Magini; A. Zambruni; C. Bendini; V. Santi; M. Bernardi; F. Trevisani

Book ID
119227893
Publisher
Elsevier Science
Year
2005
Tongue
English
Weight
125 KB
Volume
37
Category
Article
ISSN
1590-8658

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Thalidomide in the treatment of patients
Thalidomide in the treatment of patients with hepatocellular carcinoma : A Phase II trial
โœ Yehuda Z. Patt; Manal M. Hassan; Richard D. Lozano; Ajay K. Nooka; Isaac I. Schn ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 91 KB ๐Ÿ‘ 2 views

## Abstract ## BACKGROUND The treatment of patients with hepatocellular carcinoma (HCC) presents a major challenge, because associated cirrhosis limits the choice of chemotherapeutic agents. However, the abundant vascularity of HCC presents an attractive target for antiangiogenic therapy that pote

Phase 2 study of cetuximab in patients w
Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma
โœ Andrew X. Zhu; Keith Stuart; Lawrence S. Blaszkowsky; Alona Muzikansky; Donald P ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 131 KB ๐Ÿ‘ 1 views

## Abstract ## BACKGROUND. Epidermal growth factor receptor (EGFR) and ligand expression is frequently seen in hepatocellular carcinoma (HCC). A phase 2 study was performed with cetuximab, a chimeric monoclonal antibody that binds specifically to EGFR, in patients with advanced HCC. ## METHODS.